HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IGI

This article was originally published in The Rose Sheet

Executive Summary

Seeking new distributor for its dermatological products, including the Wellskin skin care line, following Glaxo Wellcome's decision to exit the U.S. physician-dispensed skin care market to focus resources on its core prescription business, IGI announced. The company said it is "seeking strategic partners for whom skin care is a product growth area" to facilitate a "smooth transition." Wellskin, introduced in 1996 under the brand name Nova Skin, was renamed in 1997 while marketed by Glaxo under an agreement with IGI ("The Rose Sheet" Dec. 1, 1997, p. 10)
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005971

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel